Tirzepatide

What tirzepatide is.

Why dual beats single.

Half-life, steady-state, titration.

Tirzepatide has a terminal half-life of approximately 5 days (~120 hours), which supports once-weekly subcutaneous administration. Steady-state plasma concentrations are reached after roughly four weeks at a given dose. Both peak concentration (Cmax) and total exposure (AUC) scale approximately proportionally with dose across the 2.5 mg to 15 mg range. Elimination is by peptidase cleavage and renal/biliary clearance of fragments; no dose adjustment is currently required for renal or hepatic impairment, though the trial program has limited data at the extremes of organ dysfunction.

On-treatment maintenance

Tirzepatide, like every drug in the class, works while it is being taken. SURMOUNT-4 (see below) was specifically designed to answer whether the effect persists after discontinuation; it does not. The pragmatic implication is that effective use is long-term use, and the dose-titration framework is also a long-term framework — the lowest dose that holds the target outcome is the correct maintenance dose.

SURMOUNT and SURPASS.

Two parallel Phase-3 programs underwrote the regulatory file: SURPASS for Type 2 Diabetes, and SURMOUNT for obesity. Both have produced effect sizes that are, at the time of writing, the largest reported for any pharmacologic intervention in their respective indications.

The grey area to name plainly: SURMOUNT and SURPASS established weight and glycemic superiority, but a cardiovascular outcomes readout comparable to SELECT (for semaglutide) is not yet available for tirzepatide. The SURPASS-CVOT trial is the file the field is waiting on. Until that data lands, claims that tirzepatide is "cardio-protective" extend the GLP-1-class signal rather than rest on its own hard-endpoint evidence.

The SURMOUNT-5 readout.

SURMOUNT-5 (Aronne et al., NEJM 2024–2025) is the trial the entire weight-loss field had been asking for: a direct, randomized head-to-head between maximum-tolerated tirzepatide and maximum-tolerated semaglutide 2.4 mg in adults with obesity but without T2D, over 72 weeks. The primary endpoint — percent change in body weight — favored tirzepatide: roughly 20.2% mean loss versus roughly 13.7% on semaglutide, a 6–7-percentage-point absolute difference that was both statistically and clinically significant. Secondary endpoints — proportion achieving ≥15% and ≥20% weight loss, waist circumference, metabolic markers — all moved the same direction.

The case for tirzepatide

Larger absolute effect on weight and on A1c. Superior to semaglutide in a properly powered head-to-head. Mechanistic argument (dual incretin receptor engagement) that is internally consistent with the trial readout. A maximum dose that genuinely outperforms, rather than just matches, the previous class leader.

The case against, or at least for caution

Semaglutide has the longer outcome record — SELECT for cardiovascular events, FLOW for renal endpoints, SUSTAIN-6 for the original T2D CV signal. Tirzepatide's equivalent outcome program is not yet read out. For a patient whose primary clinical driver is established cardiovascular disease, semaglutide currently has the stronger hard-endpoint file. For a patient whose primary driver is weight loss or glycemic control magnitude, tirzepatide has the stronger surrogate-endpoint file. The decision is more nuanced than "tirzepatide wins."

What to watch.

• Nausea (~30–35% across doses). Tachyphylactic. Worst at titration steps. Mitigations: smaller meals, lower-fat first bites, anti-emetic if persistent. Tends to be modestly less severe than equivalent-step semaglutide in head-to-head observational data.
• Diarrhea (~20–25%). Usually transient. If it persists past week 4 at a stable dose, hold the step.
• Vomiting (~10–15%). Dose-dependent. A reason to slow titration rather than push through.
• Constipation, dyspepsia, abdominal pain. Common at initiation, almost always resolve.
• Injection-site reactions. Generally mild.
• Lean mass loss (~25–40% of total mass lost, similar to GLP-1 class). The single most important behavioral mitigation is ≥1.6 g/kg protein and resistance training throughout treatment. Failing to protect lean mass is the most common preventable harm in this class.
• Sulfonylurea or insulin co-administration. Hypoglycemia risk rises; concurrent doses generally need to be reduced.

Contraindications

• Personal or family history of Medullary Thyroid Carcinoma (MTC). FDA black-box warning, based on rodent C-cell hyperplasia data. Debated clinical relevance in humans, but the contraindication stands.
• Multiple Endocrine Neoplasia type 2 (MEN-2). Same rationale as MTC.
• Prior pancreatitis. Relative contraindication; acute pancreatitis is a labelled adverse event. Monitor amylase/lipase if symptoms emerge; discontinue if confirmed.
• Severe gastroparesis. Drug exacerbates the underlying motility problem.
• Active gallbladder disease. Cholelithiasis risk rises with rapid weight loss, as it does across the class.
• Pregnancy or planned pregnancy. Wash out before conception — the 5-day half-life means roughly four weeks for full clearance.

Honest pricing.

Insurance coverage remains the dominant cost variable. For T2D with Mounjaro, coverage is broad; for obesity with Zepbound, coverage is narrower and plan-dependent, though the Lilly Direct single-dose vial program created a self-pay path at materially lower cost than the auto-injector pen. Eli Lilly's manufacturer savings card can bring eligible commercial-insurance patients meaningfully below list price; eligibility is restrictive.